Open AccessExperience of effective treatment for patients with severe psoriasis
Author(s) -
Н. В. Кунгуров,
Н. В. Зильберберг,
М. М. Кохан,
J. V. Keniksfest,
J M ZASADKEVICH
Publication year - 2012
Publication title -
vestnik dermatologii i venerologii
Language(s) - English
Resource type - Journals
eISSN - 2313-6294
pISSN - 0042-4609
DOI - 10.25208/vdv653
Subject(s) - ustekinumab , psoriasis , medicine , adverse effect , quality of life (healthcare) , dermatology , disease , adalimumab , nursing
In this study was summarized the clinical monitoring of 6 patients with a vulgar severe psoriasis receiving a short course of Ustekinumab — antagonist of IL 12/23. Clinical monitoring demonstrated high efficiency of treatment with achievement of clinical remission and appreciable improvement in all patients; conservation of remission of psoriasis process till 6 months with regress of PASI more than 75 % from initial point in 5 from 6 patients; improvement of quality of life, absence of complications and adverse events during the treatment and the subsequent observation.